在轻度至中度阿尔茨海默氏症患者中,Simufilam的第三期随机临床试验
James W Kupiec1, Anton P Porsteinsson2, Raymond S Turner3
1Cassava Sciences, Inc., 6801N. Capital of Texas Highway, Building 1, Austin, TX 78731 USA.
The journal of prevention of Alzheimer's disease
|January 7, 2026
概括
在阿尔茨海默氏症第3期试验中,西穆菲拉姆没有达到主要终点. 该药物安全且耐受性良好,但没有证明在减缓认知衰退方面具有有效性.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 阿尔茨海默病 (AD) 涉及通过α7尼古丁性乙胆受体发送β-粉样蛋白 (Aβ42) 信号,导致陶过酸化.
- 西穆菲拉姆通过结合胺A来向这种途径,旨在减少神经炎症.
研究的目的:
- 在对轻度至中度阿尔茨海默病的两项第三期临床试验中评估simufilam的疗效和安全性.
主要方法:
- 两项随机对照试验 (RETHINK和REFOCUS) 涉及50-87岁的参与者,患有轻度至中度的AD.
- 同主终点包括52-76周ADAS-Cog12和ADCS-ADL得分的变化.
- 参与者根据支持AD病理的标准进行了选择,包括血p-tau181或粉样蛋白PET扫描.
主要成果:
- 这两项试验都未能满足其共同初级,二级或探索性生物标志物终点.
- 发现西穆菲拉姆对参与者来说是安全的,并且耐受性很好.
- 在REFOCUS的轻度亚组中观察到一种缓慢认知衰退的潜在信号,但它没有持续,也没有复制.
结论:
- 在阿尔茨海默病的第三阶段试验中,西穆菲拉姆没有达到初级疗效终点.
- 该药物显示出良好的安全性和耐受性.
- 这些试验结果不支持对simufilam疗效的进一步研究.
相关概念视频
Clinical Trials: Overview
4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Clinical Trials
10.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.1K
Alzheimer's Disease: Treatment
806
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
806
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K


